Merck (MRK) ended the recent trading session at $111.01, demonstrating a +2.54% change from the preceding day's closing price ...

Merck has other promising candidates in its late-stage pipeline, such as enlicitide decanoate/MK-0616, an oral PCSK9 ...

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such ...

The average brokerage recommendation (ABR) for Merck (MRK) is equivalent to a Buy. The overly optimistic recommendations of ...

Keytruda drives over half of MRK's pharma revenues, but softer Q3 sales put investor focus on whether the blockbuster drug ...

AbbVie’s neuroscience portfolio is also contributing to top-line growth. Sales of its neuroscience drugs increased 20.3% to ...

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Eikon Therapeutics, Inc. eyes IPO to fund EIK1001 oncology pipeline; early Phase 2 data show 60% response rate. Click for ...

The Dow Jones Industrial Average itself yields modestly, but the Dogs of the Dow 2026 pack more dividend bite.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue ...